PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Pallua, J.D.* ; Schaefer, G.* ; Seifarth, C.* ; Becker, M.* ; Meding, S. ; Rauser, S. ; Walch, A.K. ; Handler, M.* ; Netzer, M.* ; Popovscaia, M.* ; Osl, M.* ; Baumgartner, C.* ; Lindner, H.* ; Kremser, L.* ; Sarg, B.* ; Bartsch, G.* ; Huck, C.W.* ; Bonn, G.K.* ; Klocker, H.*

MALDI-MS tissue imaging identification of biliverdin reductase B overexpression in prostate cancer.

J. Proteomics 91, 500-514 (2013)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
[object Object]: New biomarkers are needed to improve the specificity of prostate cancer detection and characterisation of individual tumors. In a proteomics profiling approach using MALDI-MS tissue imaging on frozen tissue sections, we identified discriminating masses. Imaging analysis of cancer, non-malignant benign epithelium and stromal areas of 15 prostatectomy specimens in a test and 10 in a validation set identified characteristic m/z peaks for each tissue type, e.g. m/z 10775 for benign epithelial, m/z 6284 and m/z 6657.5 for cancer and m/z 4965 for stromal tissue. A 10-fold cross-validation analysis showed highest discriminatory ability to separate tissue types for m/z 6284 and m/z 6657.5, both overexpressed in cancer, and a multicomponent mass peak cluster at m/z 10775-10797.4 overexpressed in benign epithelial tissue. ROC AUC values for these three masses ranged from 0.85 to 0.95 in the discrimination of malignant and non-malignant tissue. To identify the underlying proteins, prostate whole tissue extract was separated by nano-HPLC and subjected to MALDI TOF/TOF analysis. Proteins in fractions containing discriminatory m/z masses were identified by MS/MS analysis and candidate marker proteins subsequently validated by immunohistochemistry (IHC). Biliverdin reductase B (BLVRB) turned out to be overexpressed in PCa tissue. BIOLOGICAL SIGNIFICANCE: In this study on cryosections of radical prostatectomies of prostate cancer patients, we performed a MALDI-MS tissue imaging analysis and a consecutive protein identification of significant m/z masses by nano-HPLC, MALDI TOF/TOF and MS/MS analysis. We identified BLVRB as a potential biomarker in the discrimination of PCa and benign tissue, also suggesting BVR as a feasible therapeutic target.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
4.088
1.141
39
40
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Mass spectronomy tissue imaging; Prostate cancer; Tissue biomarker; Biliverdin reductase; Heme metabolism; Major Physiological Cytoprotectant ; Ix-beta Reductase ; Mass-spectrometry ; Biomarker Discovery ; Hepatocellular-carcinoma ; Oxidative Stress ; Heme Oxygenase-1 ; Protein Markers ; Ovarian-cancer ; Breast-cancer
Sprache englisch
Veröffentlichungsjahr 2013
HGF-Berichtsjahr 2013
ISSN (print) / ISBN 1874-3919
e-ISSN 1876-7737
Zeitschrift Journal of Proteomics
Quellenangaben Band: 91, Heft: 8, Seiten: 500-514 Artikelnummer: , Supplement: ,
Verlag Elsevier
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Analytical Pathology (AAP)
Institute of Pathology (PATH)
POF Topic(s) 30205 - Bioengineering and Digital Health
30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-500390-001
G-500300-001
PubMed ID 23954705
DOI 10.1016/j.jprot.2013.08.003
WOS ID WOS:000327906000040
Scopus ID 84884126478
Erfassungsdatum 2013-08-30
[➜Korrektur melden]